Department of Animal Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Recombinant Proteins Research Group, Research Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran; Department of Animal Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Microb Pathog. 2019 Jul;132:30-37. doi: 10.1016/j.micpath.2019.04.019. Epub 2019 Apr 17.
Previous studies on vaccine development against foot-and-mouth disease (FMD) virus reported that application of the inactivated vaccines for FMD virus is not completely effective. Novel vaccinations based on immune-dominant epitopes showed they induced immune responses. In addition, for better and safer immunization, access to of efficient adjuvants against FMD virus seems to be critical. In this study, we produced epitope recombinant vaccines from the VP1 protein of the FMD virus for serotype O of Iran that conjugated with Fc Immunoglobulin (FcIgG) and Interleukin-2 (IL-2). Multiple-epitope constructs included Polytope, Polytope-IL2-FcIgG, Polytope-IL2, Polytope-FcIgG that cloned and expressed in E. coli BL21 (DE3). To evaluate whether these epitope recombinant vaccines induce immune responses, BALB/c mice were injected with the epitope recombinant vaccines and their immune responses were compared with a negative control group. The humoral and cellular immune responses were measured by ELISA. The results showed there were significant differences between the negative control group and other immunized mice with recombinant epitope proteins (p < 0.05). The results of total IgG, IgG1, IgG2a levels and secretion of IFN-γ, IL-4 and IL-10 revealed that immune responses were enhanced when the epitope recombinant vaccine of FMD virus coupled with IL-2 and FcIgG. Observations indicated that the epitope recombinant plasmid of the VP1 protein co-expressed with IL-2 and FcIgG was effective in inducing an enhanced immune response. Therefore, IL-2 and FcIgG could be recommended as a potential adjuvant for epitope recombinant vaccine of the VP1 protein from FMD virus.
先前针对口蹄疫（FMD）病毒疫苗开发的研究报告称，应用 FMD 病毒灭活疫苗并非完全有效。基于免疫优势表位的新型疫苗接种已显示出它们可诱导免疫反应。此外，为了实现更好、更安全的免疫接种，获得针对 FMD 病毒的高效佐剂似乎至关重要。在这项研究中，我们从伊朗 O 型 FMD 病毒的 VP1 蛋白生产了与 Fc 免疫球蛋白（FcIgG）和白细胞介素-2（IL-2）缀合的表位重组疫苗。多表位构建体包括 Polytope、Polytope-IL2-FcIgG、Polytope-IL2 和 Polytope-FcIgG，这些构建体在 E. coli BL21（DE3）中克隆和表达。为了评估这些表位重组疫苗是否诱导免疫反应，用表位重组疫苗对 BALB/c 小鼠进行注射，并将其免疫反应与阴性对照组进行比较。通过 ELISA 测量体液和细胞免疫反应。结果表明，与阴性对照组相比，其他免疫重组表位蛋白的小鼠存在显著差异（p<0.05）。总 IgG、IgG1、IgG2a 水平以及 IFN-γ、IL-4 和 IL-10 的分泌表明，当 FMD 病毒的表位重组疫苗与 IL-2 和 FcIgG 结合时，免疫反应得到增强。观察结果表明，VP1 蛋白的表位重组质粒与 IL-2 和 FcIgG 共表达可有效诱导增强的免疫反应。因此，IL-2 和 FcIgG 可被推荐为 FMD 病毒 VP1 蛋白表位重组疫苗的潜在佐剂。
